 | Up a level |
Voegeli, Michèle; Rondeau, Stephanie; Berardi Vilei, Simona; Lerch, Erika; Wannesson, Luciano; Pabst, Thomas; Rentschler, Jochen; Bargetzi, Mario; Jost, Lorenz; Ketterer, Nicolas; Bischof Delaloye, Angelika; Ghielmini, Michele (2017). Y(90) -Ibritumomab tiuxetan (Y(90) -IT) and high-dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy: a feasibility trial (SAKK 37/05). Hematological oncology, 35(4), pp. 576-583. Wiley 10.1002/hon.2348
Stupp, Roger; Mayer, Michael; Kann, Roger; Weder, Walter; Zouhair, Abderahim; Betticher, Daniel C; Roth, Arnaud D; Stahel, Rolf A; Majno, Sabine Balmer; Peters, Solange; Jost, Lorenz; Furrer, Markus; Thierstein, Sandra; Schmid, Ralph A; Hsu-Schmitz, Shu-Fang; Mirimanoff, René-Olivier; Ris, Hans-Beat; Pless, Miklos (2009). Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial. Lancet oncology, 10(8), pp. 785-93. Oxford: Elsevier 10.1016/S1470-2045(09)70172-X
